Calliditas Therapeutics (CALT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calliditas Therapeutics has announced that the EMA’s CHMP has recommended full marketing authorization for Kinpeygo in the EU for treating primary IgA nephropathy (IgAN), a rare kidney disease. This endorsement follows the initial conditional approval granted in July 2022, aiming to broaden the treatment to a wider patient population. The European Commission is expected to finalize the decision on marketing authorization by August 2024.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.